Group items tagged

The Pharmacy Supervision Practice Group consisting of members from AIMp, APTUK, CCA, NPA, PDA, PFNI and RPS held its fourth workshop to continue discussions on the future modelling of pharmacy practice. The ideas around 'supervision' shared by the organisation earlier formed the basis of the discussion during the workshop and helped to expand understanding of where there was consensus and disagreement. Examples of ideas explored during the workshop include: the extent to which a pharmacist should supervise the medicines assembly process, the purpose and extent to which a pharmacist might be absent from the pharmacy and how this might affect patient safety as well as the nature of whether fixed rules versus a broad framework were preferable for future practice. Chair of the group, Dr Michael Twigg, Associate Professor of Primary Care Pharmacy, University of East Anglia, said "Once again the sector bodies have come together in a collaborative and positive manner to explore the concept of 'supervision' in the context of current and future community pharmacy practice. This session provided an opportunity to constructively challenge assumptions and viewpoints within the group with the aim of moving the discussion forward." As part of the session, the DHSC, GPhC and PSNI gave an overview of the difference between legislation, regulation and guidance which was helpful to inform the group's thinking. Each of the organisations have been asked to use the conversation to refine the ideas presented in advance of the next workshop.

A BBC investigation has found 20 UK online pharmacies selling prescription-only medicines without adhering to the regulatory standards, such as checking for GP approval or patient's medical records. The news organisation was able to purchase over 1,600 restricted pills, including anti-anxiety drug, painkiller and sleeping medication, from these regulated online pharmacies easily by providing false information. However, the report didn't mention the names of the drugs as "they can be dangerous when taken without medical guidance." Some pharmacies were also found selling high-risk and potentially addictive medicines, including benzodiazepines and antidepressants, based on online questionnaires and did not require further checks. The General Pharmaceutical Council (GPhC), which regulate online pharmacies in the UK, states that selling and supplying medicines at a distance brings "different risks which need to be appropriately managed to protect patient safety."

NHS England's decision to forgo commissioning puberty suppressing hormones (PSH) for children and young people, citing insufficient evidence of their safety and clinical effectiveness, follows a comprehensive review conducted by the National Institute for Health and Care Excellence (NICE) in 2020. The clinical report underscores that "PSH treatment options will not be part of routine commissioning" for people under the age of 18 in England grappling with gender incongruence or dysphoria. The NHS England review analysed nine observational studies on Gonadotrophin Releasing Hormone Analogues (GnRHa) and found no statistically significant difference in gender dysphoria, mental health, body image, and psychosocial functioning among children and adolescents treated with GnRHa. Duncan Rudkin, chief executive of the General Pharmaceutical Council (GPhC), acknowledged the challenges faced by pharmacy professionals regarding prescriptions for puberty suppressing hormones, stating:

In a bid to bolster the educational experience for undergraduate pharmacy students across London, Kingston University has embarked on a groundbreaking project in collaboration with University College London and King's College London. This initiative, fueled by a substantial £1.5 million investment from National Health Services England (NHSE), aims to elevate the quality and consistency of pharmacy placements throughout the capital for new pharmacy entrants. The project is designed to address the evolving standards set forth by the General Pharmaceutical Council (GphC), ensuring that newly-trained pharmacists are well-prepared to meet the demands of their profession. By standardizing and expanding pharmacy placements, the three universities seek to provide students with a comprehensive and diverse range of "experiential learning opportunities".

Women accounted for 62 per cent of GPhC registrants in 2019, according to the Royal Pharmaceutical Society. Despite representing the majority of pharmacists in the UK, only 2 per cent of women are pharmacy business owners compared with 13 per cent of men. Also, the majority of senior pharmacy leadership positions are held by men, with research showing that only 36 per cent of senior pharmacy leaders are women. Sobha Sharma Kandel, superintendent pharmacist and co-owner of Neem Tree Pharmacy, Abbey Wood, London, quoted these statistics while shedding light on the representation of female leaders in the field of pharmacy. So, what is stopping women from reaching leadership positions in the profession? According to Sobha, the barriers hindering female pharmacists from attaining leadership positions include: Gender Bias and Stereotypes Lack of Representation and Role Models Glass Ceiling and Double Standards Work-Life Balance Challenges Imposter Syndrome Unequal Access to Opportunities Negotiation and Advocacy Challenges "There also continue to be gender and ethnicity pay gaps affecting women in pharmacy," said Sobha, who has been advocating for women in pharmacy by being a part of the Female Pharmacy Leaders Network.

Trainee pharmacists across Great Britain are preparing to participate in Pharmacist Support's annual Trainee ACTNow Wellbeing Campaign, scheduled from May 20th to 24th. Organised by the charity, this initiative aims to provide essential support as trainees approach the culmination of their placements and gear up for the General Pharmaceutical Council (GPhC) assessment. Danielle Hunt, Chief Executive of Pharmacist Support, highlighted the campaign's focus on addressing the significant stress and pressure trainees may experience during this critical period. She stated: "We understand the anxiety and pressure they may feel, not only in preparing for the assessment but also in stepping into their roles as registered pharmacists."

A judicial review claim launched by the British Medical Association (BMA) against the General Medical Council (GMC) has parallelly intensified Pharmacists' Defence Association's (PDA) scrutiny over the use of the term 'pharmacy professionals'. PDA has criticised the evolving definition of 'pharmacy professionals,' and the potential risks to patient safety amidst regulatory ambiguity as part of "a far wider agenda." Concerns stem from what the PDA perceives as a blurring of distinctions between pharmacists and pharmacy technicians as "attempted homogenisation" by bodies like the General Pharmaceutical Council (GPhC), NHS, and Royal Pharmaceutical Society (RPS). Raising similar issue as the BMA against the GMC over its use of 'medical professionals for doctors and Medical Associate Professions (MAPs), Mark Koizol, Chairman of the PDA has said:

The General Pharmaceutical Council (GPhC) has alerted pharmacists, pharmacy technicians, and pharmacy owners via email regarding new emergency legislation governing the prescribing and supply of puberty-suppressing hormones, commonly known as 'puberty blockers', for children and young people under 18 in England, Wales, and Scotland. The regulations apply to gonadotropin-releasing hormone (GnRH) analogues, used to suppress puberty as part of treating gender incongruence or gender dysphoria in individuals under 18. Effective from 3 June 2024, new private prescriptions for GnRH analogues from prescribers in the European Economic Area (EEA) or Switzerland who are not UK registered are banned from being dispensed in Great Britain for patients under 18. The emergency ban on these medicines will remain in effect until September 3, 2024, the Department of Health and Social Care (DHSC) announced on 29 May, stating that the action has been taken to address risks to "patient safety."

Pharmacist supervision has been the subject of debate for as long as I can remember. Strikingly, no one is sure what supervision requires. The Human Medicines Regulations 2012 say it is a criminal offence to sell or supply Pharmacy medicines or Prescription Only Medicines unless a pharmacist makes the sale or supply or, if the transaction is carried out by a non-pharmacist, that person acts under the supervision of a pharmacist. Over the years, some people have argued that supervision requires a clinical check. Others say it requires an accuracy assessment. Yet others have asserted that it requires a final check before a medicine leaves the pharmacy. Things are made more uncertain by the NHS terms of service which require prescription medicines to be supplied under the direct supervision of a pharmacist. No one knows what the word "direct" adds. The wording of the Human Medicines Regulations is not identical to the wording of earlier legislation. In particular, on the only occasions when the courts have been called upon to interpret the requirement for supervision, the Pharmacy and Poisons Act 1933 was in force. In cases decided in 1943 and 1953, the courts decided that a pharmacist who was upstairs when a supply was made could not have been supervising; and that a sale was supervised by pharmacist standing at the cash desk because the pharmacist could intervene if a sale would not be appropriate.

Pharmacists working in Northern Ireland think the retention fees are too high, and most would prefer to pay in instalments, if that option is available, amid the increased living costs, a new survey has found. 97 per cent of the respondents to the survey, conducted by the Pharmacists' Defence Association (PDA) of its Northern Irish members, felt the fees were too high. Four in five said they would opt to pay in instalments if this option were available to them in light of the challenges of significant one-off payments. On average, the fees accounted for 23 per cent of a pharmacist's take-home pay for one month, and 98 per cent did not see any value added to their professional standing for the sum, according to the survey. The PDA said the respondents also reported feeling disadvantaged among their colleagues in terms of how fees are collected, with many also wondering why the registration fee was not offset for those on maternity leave or working reduced or flexible hours.

The Council of Pharmaceutical Society NI (PSNI) has introduced an 8-week public consultation on proposed Guidance on Pharmacy Staffing Levels within registered premises. The principle-based Guidance seeks to assist Pharmacy Owners and Superintendents to ensure that each pharmacy has enough appropriately skilled and qualified staff to provide safe and effective pharmacy services to the public. All registered pharmacies will have to meet the standards set out in the Premises Standards, when commenced. PSNI said: "The proposed Guidance should also help ensure a working environment that will facilitate pharmacists to meet their professional obligations under the Professional Standards of Conduct, Ethics and Performance for Pharmacists in Northern Ireland (2016)." "Whilst other health regulators have primary responsibility for systems regulation outside of regulated premises, we consider that the principles outlined in this Guidance, will be helpful for managers working with pharmacy teams in different settings."

The number of pharmacists working in community pharmacy in England has increased by 19 per cent in five years, according to new data released by the Department of Health and Social Care (DHSC). As of 31 October 2022, there were 27,711 community pharmacists in the country, as compared to 23,284 in 2017, an increase of almost 4,500. Pharmacy minister Andrea Leadsom revealed these figures yesterday (14 December) while responding to a written question from Karin Smyth, Shadow Minister of Health, in the parliament. Smyth asked - how many and what proportion of community pharmacists have worked in England for each of the last 10 years.

The Health Education England (HEE) has secured funding to further support growth of the pharmacy technician workforce in 2022/23. This support is through expansion of pre-registration trainee pharmacy technician (PTPT) training capacity in community pharmacy or as part of a cross-sector integrated apprenticeship programme. HEE will be holding two 90-minute webinars on Monday 27 2022. There will be a morning webinar (10-11.30am) and an evening webinar (7-8.30pm) for attendees to choose from. Topics like- available funding; eligibility for funding; PTPT training programme requirements for employers; how to apply for this funding; and the support available from HEE for successful funding of applicants to develop their PTPT training programmes, will be covered during the webinars. HEE is also hosting another webinar to provide an update on the Independent Prescribing (IP) for pharmacists training offer that they are developing for Autumn 2022.